Venous Thromboembolism: Prevention and Treatment

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), representing a spectrum of the same disease process. VTE is the third most common cardiovascular disease after coronary artery disease and stroke, with an annual incidence of 1-2 per 1000 individuals.

Virchow's Triad remains the fundamental framework for understanding VTE pathogenesis:

• Venous stasis: Reduced blood flow due to immobilization, surgery, or anatomical factors
• Endothelial injury: Trauma, surgery, central venous catheters, or inflammatory conditions
• Hypercoagulability: Inherited thrombophilias, malignancy, hormonal factors, or acquired conditions

⚡ HIGH-YIELD: The coagulation cascade involves both intrinsic and extrinsic pathways, ultimately leading to thrombin generation and fibrin clot formation. Factor V Leiden (most common inherited thrombophilia) and prothrombin gene mutation G20210A are the most clinically relevant genetic risk factors.

Risk Stratification is crucial for prevention and treatment decisions:

The annual recurrence rate after unprovoked VTE is approximately 10% in the first year and 5% annually thereafter. PE occurs in approximately 50% of untreated proximal DVT cases, making early recognition and treatment critical.

🔬 DIAGNOSIS Pearl: D-dimer has high sensitivity (>95%) but low specificity (~50%) for VTE. It should only be used in low-probability patients based on clinical prediction rules to avoid overuse and false positives.

Deep Vein Thrombosis Clinical Features:

• Unilateral leg swelling (most sensitive sign)
• Pain or tenderness along deep vein distribution
• Erythema and warmth
• Palpable cord (thrombosed vein)
• Homans' sign (unreliable, positive in <50% of cases)

Wells Score for DVT:

Criteria Points

Active cancer +1 Paralysis/immobilization +1 Recent bed rest >3 days or major surgery +1 Localized tenderness along deep veins +1 Entire leg swelling +1 Calf swelling >3 cm compared to other leg +1 Pitting edema +1 Collateral superficial veins +1 Alternative diagnosis likely -2

≤0 points: Low probability (3%) 1-2 points: Moderate probability (17%) ≥3 points: High probability (75%)

Pulmonary Embolism Clinical Features:

• Dyspnea (most common, 73%)
• Pleuritic chest pain (66%)
• Cough (37%)
• Hemoptysis (13%)
• Syncope (massive PE)

⚡ HIGH-YIELD Wells Score for PE:

Diagnostic Approach:

1. Low probability + negative D-dimer: VTE excluded
2. High probability or positive D-dimer: Proceed to imaging
3. DVT: Compression ultrasonography (CUS) - sensitivity >95% for proximal DVT
4. PE: CT pulmonary angiogram (CTPA) - gold standard, or V/Q scan if contrast contraindicated

💊 TREATMENT Pearl: In high clinical suspicion cases, empiric anticoagulation should be started while awaiting imaging results, unless high bleeding risk exists.

Initial Anticoagulation (First 5-10 days):

Parenteral Options:

• Unfractionated Heparin (UFH): IV infusion, aPTT monitoring, preferred in renal failure (CrCl <30 mL/min)
• Low Molecular Weight Heparin (LMWH): Enoxaparin 1 mg/kg Q12H or 1.5 mg/kg daily, no monitoring required
• Fondaparinux: 5-10 mg daily based on weight, contraindicated if CrCl <30 mL/min

Direct Oral Anticoagulants (DOACs) - First Line:

⚡ HIGH-YIELD: DOACs are preferred over warfarin due to:

• No routine monitoring required
• Faster onset of action
• Lower risk of major bleeding
• Fewer drug interactions

Warfarin Therapy:

• Start with heparin bridging (minimum 5 days overlap)
• Target INR 2.0-3.0
• Monitor INR every 2-3 days initially, then weekly to monthly
• Multiple drug and food interactions

Special Populations:

• Cancer-associated VTE: LMWH preferred for first 3-6 months
• Pregnancy: LMWH throughout pregnancy, warfarin contraindicated
• Renal impairment: UFH or dose-adjusted LMWH/DOACs
• Massive PE: Consider thrombolysis or embolectomy

🔑 KEY CONCEPT: Therapeutic anticoagulation reduces VTE recurrence by 80-90% but increases bleeding risk 2-5 fold. Risk-benefit assessment is crucial for duration decisions.

Treatment Duration Guidelines:

Provoked VTE (Reversible Risk Factor):

• Duration: 3 months minimum
• Examples: Surgery, trauma, estrogen therapy, prolonged immobilization
• Recurrence risk: Low (1-3% annually) after stopping therapy

Unprovoked VTE:

• First episode: Consider indefinite therapy if low bleeding risk
• Recurrent VTE: Indefinite anticoagulation recommended
• Recurrence risk: 7-11% first year, 5-7% annually thereafter

⚡ HIGH-YIELD Risk-Benefit Assessment:

Decision Framework for Extended Therapy:

High Recurrence Risk + Low Bleeding Risk ──────────────────────────────────────────────────── • Unprovoked VTE • Age <65 years • Recurrent VTE • No prior bleeding • Residual DVT • Good anticoagulation control • Active malignancy • No high-risk comorbidities • Antiphospholipid syndrome
• Hereditary thrombophilia

        ↓
Consider Extended Therapy

Bleeding Risk Assessment (HAS-BLED Score):

Score ≥3: High bleeding risk, consider shorter duration

Special Considerations:

• Cancer-associated VTE: Continue anticoagulation while cancer is active
• Catheter-related VTE: Remove catheter if possible, treat for 3 months
• Superficial thrombophlebitis: Anticoagulation for 45 days if >5 cm length

💊 TREATMENT Pearl: D-dimer measured 1 month after stopping anticoagulation can help predict recurrence risk. Persistently elevated levels suggest higher recurrence risk and may warrant extended therapy.

VTE Prevention (Thromboprophylaxis):

Risk Assessment - Caprini Score (Surgical Patients):

Pharmacological Prophylaxis:

Standard Dosing:

• Enoxaparin: 40 mg daily or 30 mg BID
• Dalteparin: 5000 units daily
• UFH: 5000 units Q8-12H
• Fondaparinux: 2.5 mg daily

Mechanical Prophylaxis:

• Graduated compression stockings: 15-30 mmHg pressure
• Intermittent pneumatic compression (IPC): Preferred when bleeding risk high
• Early mobilization: Most effective mechanical method

⚠️ PEARL: Combine mechanical and pharmacological prophylaxis in very high-risk patients (trauma, orthopedic surgery, cancer surgery).

Special Populations:

Medical Patients (Padua Score ≥4 or IMPROVE Score):

• Active cancer: +3 points
• Previous VTE: +3 points
• Reduced mobility: +3 points
• Thrombophilia: +3 points
• Recent trauma/surgery: +2 points
• Age ≥70: +1 point
• Heart/respiratory failure: +1 point each
• Acute infection/rheumatologic disorder: +1 point each
• Obesity (BMI ≥30): +1 point
• Hormonal therapy: +1 point

Extended Prophylaxis:

• Major cancer surgery: Up to 4 weeks post-discharge
• Hip/knee arthroplasty: 10-35 days total duration
• High-risk abdominal surgery: Consider extended prophylaxis

🔬 DIAGNOSIS Pearl: Up to 60% of hospital-acquired VTE occurs after discharge, emphasizing the importance of extended prophylaxis in appropriate patients.

Acute Complications:

Massive Pulmonary Embolism:

• Definition: Systolic BP <90 mmHg or drop >40 mmHg from baseline
• Signs: Shock, syncope, cardiac arrest
• Treatment:
  • IV thrombolysis (alteplase 100 mg over 2 hours) if no contraindications
  • Surgical embolectomy or catheter-directed therapy
  • Consider ECMO in refractory shock

Contraindications to Thrombolysis:

• Active bleeding or high bleeding risk
• Recent surgery (<14 days)
• Intracranial pathology
• Uncontrolled hypertension (>180/110 mmHg)

⚡ HIGH-YIELD: Use simplified PESI score for PE severity assessment:

Score 0: Low risk (30-day mortality <1%) Score ≥1: High risk (consider hospitalization)

Chronic Complications:

Post-thrombotic Syndrome (PTS):

• Incidence: 20-50% after DVT
• Symptoms: Chronic leg pain, swelling, skin changes
• Prevention: Compression stockings controversial
• Treatment: Graduated compression, elevation, exercise

Chronic Thromboembolic Pulmonary Hypertension (CTEPH):

• Incidence: 2-4% after acute PE
• Screening: Echocardiogram and dyspnea assessment at 3-6 months
• Diagnosis: Right heart catheterization
• Treatment: Pulmonary endarterectomy (curative)

Bleeding Complications:

Major Bleeding Management:

1. Stop anticoagulation immediately
2. Assess severity and source
3. Reversal agents if available:
   • UFH: Protamine sulfate (1 mg per 100 units heparin)
   • Warfarin: Vitamin K + 4-factor PCC
   • DOACs: Specific reversal agents when available
4. Supportive care: Transfusion, surgery if needed

💊 TREATMENT Pearl: Minor bleeding doesn't always require anticoagulation cessation. Consider dose reduction, temporary interruption, or switching agents based on bleeding severity and VTE recurrence risk.

Laboratory Monitoring:

Warfarin Monitoring:

• Initial phase: INR every 2-3 days until therapeutic
• Stable phase: INR every 4-12 weeks
• Target INR: 2.0-3.0 (2.5-3.5 for mechanical valves)
• Time in therapeutic range (TTR): Goal >70%

DOAC Monitoring:

• Routine monitoring: Not required
• Consider monitoring in:
  • Extreme body weight (<50 kg or >120 kg)
  • Renal impairment
  • Suspected overdose or bleeding
  • Drug interactions

Monitoring Tests for DOACs:

Clinical Follow-up Schedule:

Month 1:

• Assess treatment response and side effects
• Review bleeding events
• Medication adherence counseling
• Laboratory monitoring if indicated

Month 3:

• Clinical assessment for recurrent VTE
• Evaluate for post-thrombotic syndrome
• Discuss duration of therapy
• Repeat imaging if clinically indicated

Ongoing Monitoring:

• Every 3-6 months: Clinical assessment, bleeding events
• Annual assessment: Risk-benefit analysis for continuation
• Cancer patients: More frequent monitoring based on cancer status

⚠️ PEARL: Patient education is crucial for adherence:

• Bleeding signs to report: Easy bruising, prolonged bleeding, dark stools, severe headache
• Drug interactions: NSAIDs, antibiotics, other anticoagulants
• Dietary considerations: Vitamin K consistency for warfarin patients
• Activity restrictions: Avoid high-risk activities initially

Quality Metrics:

• VTE recurrence rate: <5% annually
• Major bleeding rate: <3% annually
• Treatment adherence: >80%
• Time to therapeutic anticoagulation: <24 hours

🔑 KEY CONCEPT: Long-term management requires balancing recurrence prevention with bleeding risk, necessitating regular reassessment and shared decision-making with patients.